<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene A67V;H69del;V70del;T95I;G142D;V143del;Y144del;Y145del;N211del;L212I;ins214EPE;G339D;S371L;S373P;S375F;K417N;N440K;G446S;S477N;T478K;E484A;Q493R;G496S;Q498R;N501Y;Y505H;T547K;D614G;H655Y;N679K;P681H;N764K;D796Y;N856K;Q954H;N969K literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.A67V;H69_V70del;T95I;G142D;V143_Y144_Y145del;N211del;L212I;ins214EPE;G339D;S371L;S373P;S375F;K417N;N440K;G446S;S477N;T478K;E484A;Q493R;G496S;Q498R;N501Y;Y505H;T547K;D614G;H655Y;N679K;P681H;N764K;D796Y;N856K;Q954H;N969K</span> literature reference collection</h1>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> 4th antigenic exposure with Omicron (B.1.1.529 [BA.1])(n=29) infection increased variant specific plasma antibody and memory B cell responses as well as overall increased strain specific memory in individuals aged 22 â€“79 years, median age=33.5 years. Data collected 2.4 months after 3rd vaccination.<br/> (<a href="https://doi.org/10.1101/2022.08.11.503601" class="lit_link">Wang et al. (2022)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> paired testing of vaccine sera against ancestral virus compared to Omicron BA.1 shows that 3-dose vaccine regimen provides over 50x fold increase in protection against Omicron(B.1.1.529 [BA.1]) compared to a 2-dose regimen. <br/> (<a href="https://doi.org/10.1101/2022.08.12.22278720" class="lit_link">Hao et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 3.4-fold lower (95% CI: 3.2x-3.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.<br/> (<a href="https://doi.org/10.1101/2022.06.05.494889" class="lit_link">Kurhade et al. (2022)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccinee_plasma_binding">Vaccinee plasma binding</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 28.7x-fold lower (95% CI: 0.03x-0.05) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.<br/> (<a href="https://doi.org/10.1101/2022.06.05.494889" class="lit_link">Kurhade et al. (2022)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
